Literature DB >> 18283921

Is it real? Can we win? Is it worth doing? Managing risk and reward in an innovation portfolio.

George S Day1.   

Abstract

Minor innovations make up most of a company's development portfolio, on average, but they never generate the growth companies seek. The solution, says Day--the Geoffrey T. Boisi Professor of Marketing and a codirector of the Mack Center for Technological Innovation at Wharton--is for companies to undertake a systematic, disciplined review of their innovation portfolios and increase the number of major innovations at an acceptable level of risk. Two tools can help them do this. The first, called the risk matrix, graphically reveals the distribution of risk across a company's entire innovation portfolio. The matrix allows companies to estimate each project's probability of success or failure, based on how big a stretch it is for the firm to undertake. The less familiar the product or technology and the intended market, the higher the risk. The second tool, dubbed the R-W-W (real-win-worth it) screen, allows companies to evaluate the risks and potential of individual projects by answering six fundamental questions about each one: Is the market real? Explores customers' needs, their willingness to buy, and the size of the potential market. Is the product real? Looks at the feasibility of producing the innovation. Can the product be competitive? and Can our company be competitive? Investigate how well suited the company's resources and management are to compete in the marketplace with the product. Will the product be profitable at an acceptable risk? Explores the financial analysis needed to assess an innovation's commercial viability. Last, Does launching the product make strategic sense? examines the project's fit with company strategy and whether management supports it.

Mesh:

Year:  2007        PMID: 18283921

Source DB:  PubMed          Journal:  Harv Bus Rev        ISSN: 0017-8012


  1 in total

1.  Ten simple rules for building a successful science start-up.

Authors:  Tobias Reichmuth; Collin Y Ewald
Journal:  PLoS Comput Biol       Date:  2022-04-07       Impact factor: 4.475

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.